Cargando…
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer
Bone-modifying agents (BMAs) are frequently used for the treatment of bone metastases. Both BMA and radiation therapy (RT) are effective; however, there are few studies that have evaluated the efficacy of the combination treatment. We evaluated the effectiveness of RT + BMA in breast cancer-induced...
Autores principales: | Tanaka, Hidekazu, Makita, Chiyoko, Manabe, Yuki, Kajima, Miki, Matsuyama, Katsuya, Matsuo, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299266/ https://www.ncbi.nlm.nih.gov/pubmed/32266394 http://dx.doi.org/10.1093/jrr/rraa020 |
Ejemplares similares
-
Ra223 in Bone Metastases with Osteolytic Activity
por: Costa, Renato Patrizio, et al.
Publicado: (2018) -
Dosimetric evaluation of the heart and left anterior descending artery dose in radiotherapy for Japanese patients with breast cancer
por: Tanaka, Osamu, et al.
Publicado: (2019) -
Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
por: Tanaka, Hidekazu, et al.
Publicado: (2023) -
Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy
por: Tanaka, Hidekazu, et al.
Publicado: (2021) -
Bone Microenvironment‐Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice
por: Arellano, Danna L., et al.
Publicado: (2022)